The Scotts Miracle-Gro (SMG) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
16 Jan, 2026Executive summary
Fiscal 2024 marked a pivotal turnaround, achieving all key objectives: improved margins, strong free cash flow, and strategic progress in Hawthorne, with a shift from crisis management to growth-focused strategy.
U.S. Consumer segment net sales grew 6% year-over-year, driven by new listings, promotions, and expanded shelf space.
Hawthorne segment loss improved 70% year-over-year, returning to positive EBITDA after two years of losses, with a focus on proprietary brands.
Strategic investments in marketing and innovation supported sales and brand health, while cost-reduction initiatives and operational improvements continued.
Maintained dividend without issuing new shares and established a foundation for a three-year growth plan.
Financial highlights
Full-year net sales were $3.55–$3.6 billion, flat year-over-year; U.S. Consumer sales up 6%, Hawthorne down 37%.
Adjusted EBITDA grew 20% to $539 million, with reported adjusted EBITDA at $510.1 million including $29 million in one-time charges.
Adjusted net income for FY24 was $132.0 million ($2.29 per share), up from $68.1 million ($1.21 per share) last year.
Free cash flow exceeded $1 billion over two years, with $580–$584 million generated in 2024 and inventories reduced below $600 million.
Interest expense decreased to $158.8 million, and SG&A was $559.0 million, 15.7% of net sales.
Outlook and guidance
Fiscal 2025 guidance: adjusted EBITDA of $570–$590 million (up 6–9%), U.S. consumer sales growth of 2%, and $20 million EBITDA from Hawthorne.
Gross margin expected to approach 30% in 2025, with at least $40 million in incremental brand investments.
Free cash flow projected at $250 million, CapEx at $100 million, and leverage targeted in the low 4x range by year-end.
Three-year targets: 3% annual growth, $700 million EBITDA, mid-30s% gross margin, and leverage near 3x by 2027.
Continued efforts to support an eventual separation of the Hawthorne business when timing is appropriate.
Latest events from The Scotts Miracle-Gro
- Hawthorne divestiture, margin gains, and share buyback support improved outlook.SMG
Q1 20264 Feb 2026 - Margin expansion, $150M supply chain savings, and 3% sales growth drive future value.SMG
Investor Day 20243 Feb 2026 - Q3 sales and margins surged, with net income and guidance both sharply improved.SMG
Q3 20242 Feb 2026 - All proposals passed and financial performance showed marked improvement.SMG
AGM 20262 Feb 2026 - Margin gains, innovation, and free cash flow drive a positive outlook despite topline shifts.SMG
The 44th Annual William Blair Growth Stock Conference1 Feb 2026 - Financial turnaround, board refreshment, and all proposals approved amid strong shareholder support.SMG
AGM 20259 Jan 2026 - Q1 sales and margin gains, U.S. Consumer up 11%, Hawthorne down 35%, outlook reaffirmed.SMG
Q1 20259 Jan 2026 - Strong margin and EPS growth in 2025, with further gains and buybacks expected in 2026.SMG
Q4 202529 Dec 2025 - Proxy covers director elections, pay, auditor ratification, and incentive plan amendment.SMG
Proxy Filing17 Dec 2025